Get the Stockscreener App
33.70
0.99%
0.33
After Hours:
33.80
0.10
+0.30%
Vera Therapeutics Inc stock is traded at $33.70, with a volume of 976.03K.
It is up +0.99% in the last 24 hours and down -20.89% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$33.37
Open:
$34
24h Volume:
976.03K
Relative Volume:
1.29
Market Cap:
$2.13B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-15.25
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
-2.57%
1M Performance:
-20.89%
6M Performance:
-2.74%
1Y Performance:
+125.72%
1-Day Range:
$33.34
$34.35
1-Week Range:
$32.25
$36.28
52-Week Range:
$15.37
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
33.70 | 2.13B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Analysts - Defense World
Possible Bearish Signals With Vera Therapeutics Insiders Disposing Stock - Simply Wall St
Vera Therapeutics Releases Updated Corporate Presentation Following J.P. Morgan Healthcare Conference - Defense World
When the Price of (VERA) Talks, People Listen - Stock Traders Daily
JPMorgan Chase & Co. Decreases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Head to Head Comparison: CannTrust (OTCMKTS:CNTTF) versus Vera Therapeutics (NASDAQ:VERA) - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Awards New Employee Stock Options and RSUs Worth $42.19 Per Share - StockTitan
Vera Therapeutics Stocks Surge Amid Strategic Moves - TipRanks
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider Selling - Defense World
What's Going On With Vera Therapeutics Stock?Vera Therapeutics (NASDAQ:VERA) - Benzinga
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down After Insider Selling - MarketBeat
Vera Therapeutics Highlights Atacicept Progress at Conference - TipRanks
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor - GlobeNewswire
Vera Therapeutics Secures Stanford's Novel B Cell Therapy VT-109 in Exclusive Deal - StockTitan
Vera Therapeutics CEO Marshall sells shares for $730,535 By Investing.com - Investing.com Australia
Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Trading Down 7.3%Should You Sell? - MarketBeat
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
How to Take Advantage of moves in (VERA) - Stock Traders Daily
Is Vera Therapeutics The NEXT BIG THING? Stock Price Soars! - Truth or Fiction
Vera Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Franklin Resources Inc. Sells 5,859 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Certain Options of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2024. - Marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Buys 20,223 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Position Boosted by Geode Capital Management LLC - MarketBeat
Barclays PLC Acquires 41,394 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late (NASDAQ:VERA) - Seeking Alpha
Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in Stock - MarketBeat
Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing - Marketscreener.com
Wellington Management Group LLP Sells 92,568 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by State Street Corp - MarketBeat
Lord Abbett & CO. LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Certain Class A common stock of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 15-DEC-2024. - Marketscreener.com
Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock - MarketBeat
Vera Therapeutics CEO sells shares worth over $821k By Investing.com - Investing.com Canada
Vera Therapeutics CEO sells shares worth over $821k - Investing.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Y Intercept Hong Kong Ltd - MarketBeat
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Grants $8.5M in Stock Options, RSUs to Attract Key Talent - StockTitan
Pier Capital LLC Invests $4.57 Million in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Point72 Asset Management L.P. - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):